Q3 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Financial performance Immunology ligelizumab-IgE Inhibitor Conclusions Appendix Innovation: Clinical trials Neuroscience Oncology NCT04984876 (CQGE031G12301) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Food allergy Phase 3 211 1. Proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms at Week 12 Arm 1: ligelizumab 240 mg subcutaneous injection for 52 weeks Arm 2: ligelizumab 120 mg subcutaneous injection for 52 weeks Arm 3: Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks Arm 4: Placebo 16 weeks and ligelizumab 120 mg/240 mg subcutaneous injection for 36 weeks Arm 5: Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks Participants with a medically confirmed diagnosis of IgE-mediated peanut allergy Readout Milestone(s) 2023 Publication TBD 58 Investor Relations | Q3 2023 Results References Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation